Drugs / recombinant interleukin-12

Trials 15

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT03030378 May 2018 → Dec 2026 expected metastatic malignant neoplasm National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT00054405 Dec 2002 → May 2009 neuroblastoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1 NCT00005604 Mar 2000 → Jul 2003 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00004244 Mar 2000 → Jul 2005 cutaneous melanoma, kidney cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00004074 Aug 1999 → Feb 2009 PPoma, adenoid cystic carcinoma, adrenal cortex carcinoma, anal squamous cell carcinoma +45 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00003451 Aug 1998 → Dec 2001 cancer of unknown primary site, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +2 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00003046 Aug 1997 → Oct 2001 anus cancer, gallbladder cancer, gastric cancer, malignant pancreatic neoplasm M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT01468896 Oct 2011 → Sep 2015 overdue head and neck squamous cell carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1/2 NCT00052377 Sep 2002 → Jun 2005 mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/2 NCT00002952 Jan 1997 → Aug 2002 cutaneous melanoma University of Chicago Completed No outcome recorded
Phase 25 trials
Phase 2 NCT00031733 Feb 2002 → Dec 2004 cutaneous melanoma, ocular melanoma University of Southern California Completed No outcome recorded
Phase 2 NCT00015977 Nov 2001 → Mar 2003 prostate cancer University of Chicago Completed No outcome recorded
Phase 2 NCT00026182 Oct 2001 → Feb 2005 MALT lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, nodal marginal zone B-cell lymphoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00016289 Jul 2001 → Jul 2007 malignant epithelial tumor of ovary, primary peritoneal carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00020449 Jan 2001 → May 2004 sarcoma National Cancer Institute (NCI) Completed No outcome recorded

Press releases naming this drug 30 releases

DateIssuerRelease
2026-07-21 Imunon IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer imunon.com ↗
2026-06-01 Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 iovance.com ↗
2026-01-30 PDS Biotechnology Corp. PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI pdsbiotech.com ↗
2023-10-31 Sanyou Biopharmaceuticals(Shanghai)Co., Ltd Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy sanyoubio.com ↗
2023-05-10 Transgene Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer transgene.com ↗
2023-04-19 Werewolf Therapeutics, Inc. Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research werewolftx.com ↗
2023-01-06 Transgene Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration transgene.com ↗
2022-11-10 Werewolf Therapeutics, Inc. Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting werewolftx.com ↗
2020-11-19 Alaunos Therapeutics Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting alaunos.com ↗
2020-08-17 Dragonfly Therapeutics Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program dragonflytx.com ↗
2020-08-17 Bristol-Myers Squibb Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program bms.com ↗
2019-06-27 Alaunos Therapeutics Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma alaunos.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

FieldValueCited text
Known as recombinant interleukin-12 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003451 ↗
12

NCT00026182 ↗

NCT00004244 ↗

NCT00004074 ↗

NCT00052377 ↗

NCT00054405 ↗

NCT00031733 ↗

NCT00002952 ↗

NCT00005604 ↗

NCT00020449 ↗

NCT00003046 ↗

Show 2 more sources

Known as Edodekin alfa ClinicalTrials.gov intervention name — accepted as the source's own label NCT03030378 ↗
1

NCT01468896 ↗

Known as IL-12 “pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly)” PMID 17846226 ↗ Sep 2007
Known as interleukin-12 “pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly)” PMID 17846226 ↗ Sep 2007
Modality Protein / enzyme biologic “recombinant interleukin-12” NCT00002952 ↗
Route Subcutaneous “rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)” NCT00002952 ↗